GLP-1 Medications and Lean Mass: Why Resistance Training Matters

Member Exclusive Content

Sign up to be a member to access this content.

Join now!

Already a member? Login

As GLP-1 receptor agonists continue to gain widespread use for metabolic conditions and weight management, researchers are increasingly examining their effects beyond total body weight. Recent clinical analyses suggest that while these medications can significantly reduce body mass, a proportion of that loss may include lean tissue. This has implications for long-term metabolic health, functional capacity, and resting energy expenditure.

Emerging evidence indicates that resistance training and adequate protein intake may attenuate lean mass losses during pharmacologically assisted weight reduction. Exercise appears to preserve skeletal muscle and improve insulin sensitivity independently of medication use. Experts caution that medication without structured strength training may increase risk of sarcopenia, particularly in older adults.

For fitness professionals, the takeaway is not to weigh in on medication decisions but to recognize a shifting client population. Individuals using GLP-1 therapies may benefit from proactive programming that prioritizes muscle retention, strength progression, and protein adequacy. As pharmacological tools expand, exercise remains central to preserving metabolic resilience.